Compare ITGR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | ICUI |
|---|---|---|
| Founded | 1970 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.6B |
| IPO Year | 2000 | 1995 |
| Metric | ITGR | ICUI |
|---|---|---|
| Price | $126.36 | $152.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $91.14 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 714.6K | 184.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | 1.17 | ★ 1.96 |
| Revenue | $1,853,637,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $6.53 | $4.46 |
| P/E Ratio | $108.03 | ★ $78.02 |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $62.00 | $112.50 |
| 52 Week High | $126.80 | $192.85 |
| Indicator | ITGR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 76.12 | 26.54 |
| Support Level | $124.84 | $146.59 |
| Resistance Level | $126.80 | $160.22 |
| Average True Range (ATR) | 0.30 | 4.61 |
| MACD | -0.69 | -2.03 |
| Stochastic Oscillator | 71.20 | 5.18 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.